EPHA2 and cancer: For this reason, it is not surprising that newly synthesized molecules, endowed with agonist [23] or antagonist [32] properties, were pharmacologically characterized in prostate cell lines and, in particular, in PC3 cells, naturally overexpressing EphA2, the most studied Eph receptor in cancer.